NO20051641L - Improved imaging agents comprising barbituric acid derivatives - Google Patents

Improved imaging agents comprising barbituric acid derivatives

Info

Publication number
NO20051641L
NO20051641L NO20051641A NO20051641A NO20051641L NO 20051641 L NO20051641 L NO 20051641L NO 20051641 A NO20051641 A NO 20051641A NO 20051641 A NO20051641 A NO 20051641A NO 20051641 L NO20051641 L NO 20051641L
Authority
NO
Norway
Prior art keywords
imaging
imaging agents
barbituric acid
acid derivatives
improved imaging
Prior art date
Application number
NO20051641A
Other languages
English (en)
Inventor
Klaus Kopka
Hans-Jorg Breyholz
Stefan Wagner
Michael Schafers
Bodo Levkau
Benedictc Guilbert
Duncan Wynn
Original Assignee
Amersham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amersham Plc filed Critical Amersham Plc
Publication of NO20051641L publication Critical patent/NO20051641L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0438—Organic X-ray contrast-enhancing agent comprising an iodinated group or an iodine atom, e.g. iopamidol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Foreliggende oppfinnelsen angår diagnostiske avbildingsmidler for in vivo avbilding. Avbildingsmidlene omfatter et syntetisk barbitursyrederivat merket i 5-posisjon med en avbildingsdel som egner seg for diagnostisk avbilding in vivo. Oppfinnelsen tilveiebringer også fannasøytiske og radiofarmasøytiske sammensetninger som omfatter avbildingsmidlene, sammen med utstyrene for fremstilling av radiofarmasøytika. Videre er det beskrevet chelator -konjugater av barbitursyrederivatet, som egner seg for fremstilling av avbildingsmidler som omfatter et radioaktivt eller paramagnetisk metallion. Avbildingsmidlene er nyttige for diagnostisk avbilding in vivo av forskjellige sykdomstilstander, inkludert aterosklerose.
NO20051641A 2002-10-08 2005-04-04 Improved imaging agents comprising barbituric acid derivatives NO20051641L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0223249.4A GB0223249D0 (en) 2002-10-08 2002-10-08 Improved imaging agents
PCT/GB2003/004351 WO2004032936A1 (en) 2002-10-08 2003-10-08 Improved imaging agents comprising barbituric acid derivatives

Publications (1)

Publication Number Publication Date
NO20051641L true NO20051641L (no) 2005-06-02

Family

ID=9945439

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051641A NO20051641L (no) 2002-10-08 2005-04-04 Improved imaging agents comprising barbituric acid derivatives

Country Status (10)

Country Link
US (1) US20060120956A1 (no)
EP (1) EP1549317A1 (no)
JP (1) JP2006505550A (no)
CN (1) CN1720050A (no)
AU (1) AU2003273505B2 (no)
CA (1) CA2501136A1 (no)
GB (1) GB0223249D0 (no)
NO (1) NO20051641L (no)
RU (1) RU2005109272A (no)
WO (1) WO2004032936A1 (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006021495A1 (de) * 2006-05-09 2007-11-15 Bayer Schering Pharma Ag Verwendung von perfluoralkylhaltigen Metallkomplexen als Kontrastmittel zur Diagnose der Alzheimer Krankheit
GB0612333D0 (en) * 2006-06-21 2006-08-02 Ge Healthcare Ltd Radiopharmaceutical products
JP5916039B2 (ja) 2006-06-21 2016-05-11 ジーイー・ヘルスケア・リミテッド 放射性医薬品製品
RU2473361C9 (ru) * 2007-05-16 2013-06-20 ДжиИ Хелткер АС Меченые пептиды, связывающие фактор роста гепатоцитов (hgf), для визуализации
GB0718386D0 (en) * 2007-09-21 2007-10-31 Ge Healthcare As Improved radiopharmaceutical formulation
GB201115937D0 (en) 2011-09-14 2011-10-26 Univ Aberdeen 18F-labelled compounds for use as positron emission imaging agents
AU2019323712A1 (en) * 2018-08-24 2021-02-25 Xeniopro GmbH Aromatic molecules for use in the treatment of pathological conditions

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3952971A (en) * 1971-11-09 1976-04-27 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Airfoil shape for flight at subsonic speeds
US3952091A (en) * 1974-10-23 1976-04-20 Hoffmann-La Roche Inc. Simultaneous multiple radioimmunoassay
GB1527416A (en) * 1976-07-20 1978-10-04 Ciba Geigy Ag Photopolymerisible diepoxides
US6472227B1 (en) * 1986-06-04 2002-10-29 Abbott Laboratories Barbiturate assay, tracers, immunogens, antibodies and kit
US5102786A (en) * 1987-05-21 1992-04-07 Pb Diagnostic Systems, Inc. Biological diagnostic assay system
WO1999060018A1 (en) * 1998-05-15 1999-11-25 Nycomed Amersham Plc Labelled glutamine and lysine analogues
US6656448B1 (en) * 2000-02-15 2003-12-02 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
DE60114022T2 (de) * 2000-05-30 2006-07-13 Board Of Governors Of Wayne State University, Detroit Matrix metalloproteinase-inhibitoren
EP1332136A2 (en) * 2000-10-26 2003-08-06 Pfizer Products Inc. Pyrimidine-2,4,6-trione metalloproteinase inhibitors
HUP0301577A3 (en) * 2000-10-26 2006-02-28 Pfizer Prod Inc Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors, pharmaceutical compositions containing them and their use
AU2002222747A1 (en) * 2000-12-12 2002-06-24 Angiolab, Inc. Composition comprising melissa leaf extract for anti-angiogenic and matrix metalloproteinase inhibitory activity
GB0115929D0 (en) * 2001-06-29 2001-08-22 Nycomed Amersham Plc Solid-phase electrophilic fluorination

Also Published As

Publication number Publication date
CN1720050A (zh) 2006-01-11
US20060120956A1 (en) 2006-06-08
CA2501136A1 (en) 2004-04-22
RU2005109272A (ru) 2006-01-27
AU2003273505B2 (en) 2007-04-19
AU2003273505A1 (en) 2004-05-04
GB0223249D0 (en) 2002-11-13
JP2006505550A (ja) 2006-02-16
WO2004032936A1 (en) 2004-04-22
EP1549317A1 (en) 2005-07-06

Similar Documents

Publication Publication Date Title
NO20051641L (no) Improved imaging agents comprising barbituric acid derivatives
NO20064676L (no) Farmasoytiske salter av 3-0-(3'3'-dimetylsuccinyl)betulinsyre
NO931631L (no) Kompleksdannende midler og maalsoeking av radioaktive immunoreagenser nyttige innen terapeutiske og diagnostiske bildedannende sammensetninger og fremgangsmetoder
WO2005053752A3 (en) Novel imaging agents comprising caspase-3 inhibitors
CY1112401T1 (el) Παραγωγα πυριδαζινης
MXPA04009435A (es) Derivados de quinolina y quinolinona radiomarcados y su uso como ligandos de receptor de glutamato metabotropico.
IL124411A0 (en) Lipopolyamines as transfection agents and pharmaceutical uses thereof
DE3773237D1 (de) Einen makrozyklischen koordinat und einen antikoerper enthaltende konjugatverbindung.
NO20021205L (no) Faste lipid formuleringer
HK1081884A1 (en) Radiolabeled conjugates based on substance p and the uses thereof
WO2001092283A3 (en) Cobalamin compounds useful as cardiovascular agents and as imaging agents
CY1112139T1 (el) Μια φαρμακευτικη συνθεση περιλαμβανουσα κρυσταλλικη ριτοναβιρη μορφη ιι και ενα παρασκευασμα εξ αυτης
DK0702570T3 (da) Technetium-99m-mærkede peptider til afbildning af inflammation
BR0210965A (pt) Conjugado de quelador, complexo de radiometal, radiofármaco, kit para a preparação do mesmo, composto, e, processo para a preparação do mesmo
WO2002062398A3 (en) Radioactively labelled conjugates of phosphonates
BR0012429A (pt) Fórmulações para il-11
EP2316493A3 (en) Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
NO20051811D0 (no) Conjugates of TC complexes and targeting moiettes and their use in mri diagnostic
EE200200281A (et) Pikornaviirusevastased ühendid ja kompositsioonid, nende farmatseutilised kasutusalad ning ained nende sünteesiks
AU2002350950A1 (en) Compounds for imaging alzheimer's disease
BRPI0408848A (pt) formulações orais de cladribine
DE3164763D1 (en) Anthracycline glycosides, process for the preparation thereof, intermediate compounds and their preparation and pharmaceutical compositions
TR200100125T2 (tr) Çok döngülü tiyazolidin-2-iliden aminleri, bunların üretimi için yöntemler
TW200740428A (en) Substituted propanamide derivatives and pharmaceutical compositions thereof
ECSP045372A (es) Inhibidores de la carboxipeptidasa b plasmática

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application